Meta AnalysisID 7327
使用0.01%阿托品预防近视进展是否值得？一项Meta分析
CRD42023463605
The efficacy and safety of 0.01% atropine in slowing myopia progression and in which ocular conditions (race, myopic refraction, axial length, age, and duration) the drug is more effective.
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 7327
- Evidence Id
- 15885
- Core Evidence Id
- 15885
- Source Meta Analysis Id
- 7315
- Herb2 Meta Analysis Id
- HBMA007315
- Crd Id
- CRD42023463605
- Title
- Is it worth using 0.01% atropine to prevent myopia progression？ A Meta-Analysis
- Review Question
- The efficacy and safety of 0.01% atropine in slowing myopia progression and in which ocular conditions (race, myopic refraction, axial length, age, and duration) the drug is more effective.
- Study Type Included
- Randomized controlled trials
- Condition Being Studied
- The efficacy and safety of low concentration atropine in slowing the progression of myopia has been demonstrated in many clinical studies. At present, 0.01% atropine eye drops are often given to patients by ophthalmologists as a starting concentration, but whether this concentration can really prevent the progression of myopia and reduce the growth of axial length is controversial. It is also unclear which eye condition (race, myopic refraction, axial length, age and duration) is more effective during medication. It is also unclear exactly in which eye condition the medication is more effective. It is therefore necessary to conduct a meta-analysis of relevant RCTs to assess the role of 0.01% atropine in myopia prevention and control.
- Participant
- Inclusion criteria: Acquired myopia diagnosed by cycloplegic autorefraction Less than 18 years old Exclusion Criteria: Other eye diseases History of eye surgery Medical treatment other than low concentration atropine (e.g. orthokeratology, ) to prevent myopia progression
- Animal
- Human Disease Modelled
- Intervention
- 0.01% atropine was the main intervention.
- Comparator Control
- The control group was treated with placebo.
- Main Outcome
- The changes of ocular axial length and myopic refraction after treatment will be extracted to evaluate the efficacy of 0.01% atropine. The intraocular pressure, amplitude of accommodation, pupil diameter, and adverse effects incidence will be extracted to evaluate the safety of 0.01% atropine.
- Outcome Measure
- Additional Outcome
- Study Method
- Meta-analysis, Systematic review
- Keyword
- MeSH headings have not been applied to this record
- Contact
- Xinyu Jia [email protected]
- Organisational Affiliation
- Tianjin Women's and Children's Health Center
- Funding Source
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2023-09-14
- Registration Date
- 2023-09-25
- Anticipated Start Date
- 2023-09-17
- Anticipated Completion Date
- 2024-09-17
- Title Cn
- 使用0.01%阿托品预防近视进展是否值得？一项Meta分析
- Title En
- Is it worth using 0.01% atropine to prevent myopia progression？ A Meta-Analysis
- Bilingual Status
- complete